Dror Harats - Vascular Biogenics CEO, Director
| VBLTDelisted Stock | USD 0.16 0.01 5.88% |
CEO
Prof. Dror Harats serves as Chief Executive Officer and Director of Vascular Biogenics Ltd since January 2001. He has founded the Company in 2000 and has served as its Chief Executive Officer since then. His work experience includes the following roles Chairman of the Bert W. Strassburger Lipid Center at the Chaim Sheba Medical Center at Tel Hashomer Hospital and Chairman of its Institute Review Board, Professor of Medicine in the Departments of Internal Medicine and Biochemistry at the Sackler Faculty of Medicine at TelAviv University, Visiting Scientist at Syntax Discovery Research and Observer on the board of directors of Art Healthcare Ltd. Prof. Harats holds a Doctorate of Medicine degree from Hadassah Medical School at the Hebrew University of Jerusalem and has conducted postdoctoral work at the University of California, San Francisco, US. since 2001.
| Age | 59 |
| Tenure | 23 years |
| Professional Marks | Ph.D |
| Phone | 972 8 993 5000 |
| Web | https://www.vblrx.com |
Vascular Biogenics Management Efficiency
The company has return on total asset (ROA) of (0.2912) % which means that it has lost $0.2912 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5952) %, meaning that it created substantial loss on money invested by shareholders. Vascular Biogenics' management efficiency ratios could be used to measure how well Vascular Biogenics manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 564 K in liabilities with Debt to Equity (D/E) ratio of 0.05, which may suggest the company is not taking enough advantage from borrowing. Vascular Biogenics has a current ratio of 3.97, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Vascular Biogenics until it has trouble settling it off, either with new capital or with free cash flow. So, Vascular Biogenics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Vascular Biogenics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Vascular to invest in growth at high rates of return. When we think about Vascular Biogenics' use of debt, we should always consider it together with cash and equity.
Similar Executives
| Found 8 records | CEO Age | ||
| Paula Ragan | X4 Pharmaceuticals | 54 | |
| Mel MD | Galera Therapeutics | 67 | |
| Jeremy MBA | Day One Biopharmaceuticals | 53 | |
| Thomas MBA | Transcode Therapeutics | 72 | |
| Gerrit Dispersyn | Phio Pharmaceuticals Corp | N/A | |
| Daniel MBA | Acumen Pharmaceuticals | 53 | |
| Thomas Jensen | Allarity Therapeutics | 46 | |
| Amy MBA | Terns Pharmaceuticals | 53 | |
Management Performance
| Return On Equity | -0.6 | |||
| Return On Asset | -0.29 |
Vascular Biogenics Leadership Team
Elected by the shareholders, the Vascular Biogenics' board of directors comprises two types of representatives: Vascular Biogenics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Vascular. The board's role is to monitor Vascular Biogenics' management team and ensure that shareholders' interests are well served. Vascular Biogenics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Vascular Biogenics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Dror Harats, CEO, Director | ||
| Amos Ron, CFO | ||
| Samuel Backenroth, Chief Officer | ||
| Bennett Shapiro, Non-Executive Independent Chairman of the Board | ||
| Naamit Sher, VP of Devel. and Regulatory | ||
| Ayelet Horn, General Counsel, Company Secretary | ||
| Philip Serlin, Non-Executive Independent Director | ||
| Dan Gelvan, Non-Executive Independent Director | ||
| Eyal Breitbart, Vice President Research | ||
| Ron Cohen, Non-Executive Independent Director | ||
| Pr MD, CEO Director | ||
| Tami MD, VP Devel | ||
| Ruth Alon, Non-Executive Independent Director | ||
| Erez Feige, Vice President - Business Operations | ||
| Ruth Arnon, Non-Executive Independent Director | ||
| Yael Cohen, Vice President - Clinical Development | ||
| Erez MBA, Sr Operations | ||
| Jacob George, Chief Scientific Officer | ||
| Jecheskiel Gonczarowski, Non-Executive Independent Director | ||
| Deborah Scott, Managing Communications | ||
| Jide Zeitlin, Non-Executive Independent Director | ||
| Advocate Horn, G Counsel |
Vascular Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Vascular Biogenics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.6 | |||
| Return On Asset | -0.29 | |||
| Operating Margin | (33.89) % | |||
| Current Valuation | (10.99 M) | |||
| Shares Outstanding | 77.64 M | |||
| Shares Owned By Insiders | 13.48 % | |||
| Shares Owned By Institutions | 14.00 % | |||
| Number Of Shares Shorted | 250.34 K | |||
| Price To Earning | (9.32) X | |||
| Price To Book | 0.35 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.
Other Consideration for investing in Vascular Stock
If you are still planning to invest in Vascular Biogenics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Vascular Biogenics' history and understand the potential risks before investing.
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Transaction History View history of all your transactions and understand their impact on performance |